Growth hormone treatment for HIV patients improves abdominal fat, but worsens glucose levelAugust 04, 2008For human immunodeficiency virus (HIV)-infected patients with treatment-related abdominal obesity and growth hormone deficiency, receiving low-dose growth hormone resulted in improvement in fat and blood pressure measurements but worsened glucose levels, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS. Steven Grinspoon, M.D., of Massachusetts General Hospital, Boston, presented the findings of the study at a JAMA media briefing on HIV/AIDS. Patients with HIV infection treated with antiretroviral therapy frequently develop changes in body composition, such as abdominal obesity, and metabolic complications of dyslipidemia (disorders of lipoprotein metabolism, including high cholesterol levels) and insulin resistance, putting these patients at increased cardiovascular risk. Growth hormone (GH) secretion is reduced in patients with HIV and abdominal fat accumulation, and relative GH deficiency (GHD) is observed in approximately one-third of such patients, according to background information in the article. Some studies have indicated that doses of growth hormone could decrease abdominal fat. Dr. Grinspoon and colleagues conducted a study to determine whether low-dose GH in 56 HIV patients with abdominal fat accumulation and GH deficiency would improve body composition, lipids, and other metabolic and cardiovascular measures. Patients were randomly assigned to receive by injection either GH or matching placebo. Fifty-five patients (26 with GH and 29 with placebo) were included in the safety analyses and 52 patients (25 with GH and 27 with placebo) were included in the efficacy analyses. The researchers found that abdominal fat decreased significantly in the GH group compared with the placebo group, with a percentage change in the GH group of −8.5 percent and −1.6 percent in the placebo group. Trunk-to-lower extremity fat ratio and trunk fat also decreased in the GH group compared with the placebo group. Triglycerides and diastolic blood pressure (BP) levels improved with GH, while the change in systolic BP was not statistically different compared with placebo. Total cholesterol and high density lipoprotein (HDL) cholesterol levels were unchanged between the two groups. GH increased glucose levels during glucose tolerance testing, however long-term indices of glucose, hemoglobin A1c (the substance of red blood cells that carries oxygen to the cells and sometimes joins with glucose), were not different between the groups. "Data from our randomized, placebo-controlled trial involving a long duration of observation inject a note of caution into the debate regarding the use of GH therapy in the HIV population," the authors write. "Low-dose physiological GH is well-tolerated and results in significant but more modest reduction in visceral adipose tissue [VAT; abdominal fat], but is nonetheless associated with increased glucose levels. Therefore, the therapeutic window to achieve an optimal risk-benefit ratio of GH in individuals with HIV, abdominal fat accumulation, and insulin resistance may be very narrow and difficult to achieve." "Growth hormone is not yet FDA-approved for the treatment of abdominal fat accumulation in patients with HIV. Other more potent strategies to safely increase GH and reduce VAT, including the use of GH-releasing hormone (GHRH), may be more beneficial. In addition, strategies using diet, exercise, and lifestyle change may be more cost-effective in the long run than GH, particularly in patients with HIV, visceral adiposity, and insulin resistance, in whom changes in glucose may be counterproductive," the researchers conclude. JAMA and Archives Journals |
|||||||||||||||||||||
| Related Growth Hormone Current Events and Growth Hormone News Articles Parasite growth hormone pushes human cells to liver cancer Scientists have found that the human liver fluke (Opisthorchis viverrini) contributes to the development of bile duct (liver) cancer by secreting granulin, a growth hormone that is known to cause uncontrolled growth of cells. Risk of frailty in older women dependent on multisystem abnormalities A study published online ahead of press in the Gerontology Society of America's Journal of Gerontology: Medical Sciences reports that the condition of frailty in older adults is associated with a critical mass of abnormal physiological systems, over and above the status of each individual system, and that the relationship is nonlinear. Nanodiamonds deliver insulin for wound healing Bacterial infection is a major health threat to patients with severe burns and other kinds of serious wounds such as traumatic bone fractures. Study provides documentation that tumor 'stem-like cells' exist in benign tumors Cancer stem-like cells have been implicated in the genesis of a variety of malignant cancers. Research scientists at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute have isolated stem-like cells in benign (pituitary) tumors and used these "mother" cells to generate new tumors in laboratory mice. Appetite-stimulating hormone is first potential medical treatment for frailty in older women Older women suffering from clinical frailty stand to benefit from the first potential medical treatment for the condition, according to a study presented today by Penn Medicine researchers at ENDO, The Endocrine Society's 91st Annual Meeting. 'Mirthful Laughter,' Coupled With Standard Diabetic Treatment, Raises Good Cholesterol And May Lower Heart Attack Risk The connection between the body, mind and spirit has been the subject of conventional scientific inquiry for some 20 years. The notion that psychosocial and societal considerations have a role in maintaining health and preventing disease became crystallized as a result of the experiences of a layman, Norman Cousins. In the 1970s, Cousins, then a writer and magazine editor of the popular Saturday Review, was diagnosed with an autoimmune disease. Understanding natural crop defenses Ever since insects developed a taste for vegetation, plants have faced the same dilemma: use limited resources to out-compete their neighbors for light to grow, or, invest directly in defense against hungry insects. Growth hormone treatment after weight loss surgery prevents loss of muscle mass Growth hormone treatment for six months after weight loss surgery reduces patients' losses in lean body mass and skeletal muscle mass, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Hormone therapy helps short children grow up Growth hormone treatment may significantly increase final height in children diagnosed with short stature, even in cases where the child is not growth hormone deficient, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). An Anti-Frailty Pill for Seniors? Researchers at the University of Virginia Health System report that a daily single oral dose of an investigational drug, MK-677, increased muscle mass in the arms and legs of healthy older adults without serious side effects, suggesting that it may prove safe and effective in reducing age-related frailty. More Growth Hormone Current Events and Growth Hormone News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||